MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera
Status:
Recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
The trial will be a phase III, randomised-controlled, multi-centre, international, open-label
trial consisting of ruxolitinib versus best available therapy, where best available therapy
is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC),
and which will be elected by the Investigator prior to randomisation.
Phase:
Phase 3
Details
Lead Sponsor:
University of Birmingham
Collaborators:
MPN Voice National Cancer Institute, France Novartis